752135-63-0

Basic information

• Product Name: Carbamic acid, (2-hydroxy-1-methylpropyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (2-hydroxy-1-methylpropyl)-, 1,1-dimethylethyl ester (9CI);tert-butyl (3-hydroxybutan-2-yl)carbaMate;3-(Boc-amino)-2-butanol
• CAS NO: 752135-63-0
• Molecular Formula: C9H19NO3
• Molecular Weight: 189.25206
• Product Categories: N-BOC
• Mol File: 752135-63-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 286.5±23.0 °C(Predicted)
• Appearance: /
• Density: 1.008±0.06 g/cm3(Predicted)
• PKA: 12.41±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, (2-hydroxy-1-methylpropyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (2-hydroxy-1-methylpropyl)-, 1,1-dimethylethyl ester (9CI)(752135-63-0)
• EPA Substance Registry System: Carbamic acid, (2-hydroxy-1-methylpropyl)-, 1,1-dimethylethyl ester (9CI)(752135-63-0)

Safety Data

• Hazardous Substances Data: 752135-63-0(Hazardous Substances Data)

Upstream product

• 6270-16-2 3-nitrobutan-2-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 42551-55-3 3-aminobutan-2-ol 
• 3744-87-4 N-t-butyloxycarbonyl-DL-alanine 
• 342603-65-0 (+/-)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate 

Relevant articles and documents

Heterocyclic Compound

The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.